Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
2026-03-02 12:20:00 ET
CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions that might otherwise be difficult to treat.
The company already has a promising approved therapy in Casgevy, which regulators first approved in 2023 to treat patients with sickle cell disease. It has also obtained approval as a treatment for transfusion-dependent beta thalassemia.
But the issue with CRISPR is that it's been a slow rollout, and its business continues to incur significant losses. Is it still too risky a stock to buy right now? Should you consider holding off on buying CRISPR Therapeutics?
NASDAQ: CRSP
CRSP Trading
-5.35% G/L:
$50.84 Last:
4,111,575 Volume:
$52.12 Open:
